Neuroscience Bulletin

, Volume 23, Issue 1, pp 58–65

Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer’s disease?


DOI: 10.1007/s12264-007-0009-y

Cite this article as:
Li, L. Neurosci. Bull. (2007) 23: 58. doi:10.1007/s12264-007-0009-y


Glucagon-like peptide-1 (GLP-1) has been endorsed as a promising and attractive agent in the treatment of type 2 diabetes mellitus (T2DM). Both Alzheimer’s disease (AD) and T2DM share some common pathophysiologic hallmarks, such as amyloid β(Aβ), phosphoralation of tau protein, and glycogen synthase kinase-3. GLP-1 possesses neurotropic properties and can reduce amyloid protein levels in the brain. Based on extensive studies during the past decades, the understanding on AD leads us to believe that the primary targets in AD are the Aβ and tau protein. Combine these findings, GLP-1 is probably a promising agent in the therapy of AD. This review was focused on the biochemistry and physiology of GLP-1, communities between T2DM and AD, new progresses of GLP-1 in treating T2MD and improving some pathologic hallmarks of AD.


glucagon-like peptide 1 type 2 diabetes mellitus Alzheimer’s disease 

胰高血糖素样多肽1 — 治疗糖尿病的多肽, 是治疗阿尔茨海默病的新希望?


胰高血糖素样多肽1(Glucagon-like peptide, GLP)已被证明是有前景的II型糖尿病(Type 2 diabetes mellitus, T2DM)治疗剂。 阿尔茨海默病(Alzheimer’s disease, AD)和T2DM具有在淀粉样蛋 β(Amyloid β, Aβ), tau 蛋白磷酸化和葡萄糖合成酶3等方面的共同的病理生理特征。 GLP-1 具有神经营养特性, 并能降低脑淀粉样蛋白水平。 过去几十年对AD的广泛研究使我们认识到对其治疗应针对Aβ 和 tau 蛋白。 总结这些之后发现, GLP-1 可能有希望用于治疗AD。 本文综述了GLP-1的生物化学和生理学特征, T2DM和AD的共同的病理生理特征, 以及GLP-1 在治疗T2MD和改善AD某些病理变化方面的新进展。


胰高血糖素样多肽1 II 型糖尿病 阿尔茨海默病 

CLC number


Copyright information

© Shanghai Institutes for Biological Sciences 2007

Authors and Affiliations

  1. 1.Gerontology InstituteShanxi Medical UniversityTaiyuanChina

Personalised recommendations